Across TCGA pan-cancer cohorts, PPT2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PPT2 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PPT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PPT2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where PPT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.309	0.888	<.001	48	view →
LUAD	DFS	Median	II,III,IV	0.182	0.861	.004	10	view →
LSCC	DFS	Median	III,IV	0.432	0.926	.044	2	view →
CCRCC	OS	Median	All	1.000	0.803	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PPT2 tumor-vs-normal RNA expression · all PPT2 data types